DepPrior: integrating CRISPR dependency predictability with multi-omics reproducibility to prioritize candidate LUAD therapeutic targets
Frontiers in Pharmacology · 27.08.2026 · 17
DOI: 10.3389/fphar.2026.1859926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 27.08.2026. Verfasst von Feng Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Changde First People's Hospital, Changde, Hunan, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD) remains molecularly heterogeneous, and many tumors lack clearly tractable vulnerabilities. We developed DepPrior, a computational framework that ranks candidate LUAD therapeutic targets by requiring concordant evidence of CRISPR dependency separability, molecular predictability, and cross-cohort expression/protein reproducibility. DepMap dependency scores were modeled from matched expression and copy-number features using linear and non-linear learners, and gene-level AUROC and R 2 were combined into a heuristic DepScore. The final candidate set included FERMT2, CRKL, MYC, CHMP4B and related genes. The set formed a coherent tumor expression module in TCGA-LUAD, was strongly associated with proliferation-linked features, and showed rank-based concordance across GEO transcriptomic cohorts and CPTAC transcriptomic/proteomic resources. Five-fold cross-validation supported the ranking of non-linear models, although performance gains were moderate and should be interpreted as model-ranking evidence rather than as large effect-size proof. Orthogonal experiments in HCC827 cells showed modest but reproducible protein-level reductions after FERMT2 and CRKL knockdown, accompanied by a directionally stronger apoptosis-associated protein shift after combined suppression than after single perturbation. These findings support DepPrior as a reproducibility-oriented, hypothesis-generating approach for target nomination. Because cross-cohort expression concordance does not prove patient-tumor dependency conservation, and experimental validation was restricted to selected genes and cell-line systems without rescue or proliferation/clonogenic assays, the prioritized genes should be considered candidates for further perturbation, rescue, patient-derived model, and therapeutic tractability studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Changde First People's Hospital, Changde, Hunan, China.
Zitieren
APA
Zhou, F., Wang, C., Mo, L., Sun, X., & Zhang, J. (2026). DepPrior: integrating CRISPR dependency predictability with multi-omics reproducibility to prioritize candidate LUAD therapeutic targets. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1859926
Vancouver
Zhou F, Wang C, Mo L, Sun X, Zhang J. DepPrior: integrating CRISPR dependency predictability with multi-omics reproducibility to prioritize candidate LUAD therapeutic targets. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1859926
BibTeX
@article{Zhou2026,
author = {Zhou, Feng and Wang, Cheng and Mo, Lizhi and Sun, Xuan and Zhang, Ji},
title = {DepPrior: integrating CRISPR dependency predictability with multi-omics reproducibility to prioritize candidate LUAD therapeutic targets},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1859926}
}
EUVIMED